Gill P G, Jones A M, Abbott R
Aust N Z J Surg. 1983 Jun;53(3):237-40. doi: 10.1111/j.1445-2197.1983.tb02434.x.
Twenty-eight patients with inoperable or metastatic gastric cancer were treated with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C (FAM). Twenty-one patients had measurable disease parameters and 57 per cent of these experienced a major regression of disease following chemotherapy. The median survival of the responding patients was 13.2 months compared with 6.8 months in the group who did not achieve a major response. These results demonstrate the sensitivity of gastric carcinoma to this drug combination.
